- Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo
- Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments
Reported Saturday, Johnson & Johnson's Phase 2 DAHLIAS Study Reveals Nipocalimab Yields Over 70% Improvement in Sjögren's Disease Activity Compared To Placebo
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.